Trial Profile
Apatinib combined with metronomic S-1 as first-line treatment in patients with advanced primary liver cancer: a multi-center, single-arm, prospective, open-label phase II clinical trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Gimeracil/oteracil/tegafur
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- 28 Jul 2017 New trial record